北交所市场点评：震荡整固，关注商业航天、AI手机

Investment Rating - The report does not explicitly state an investment rating for the industry, but it highlights structural opportunities in sectors like commercial aerospace and AI mobile phones, suggesting a positive outlook for these areas [3]. Core Insights - The market experienced a short-term adjustment primarily due to the pullback in previously popular sectors such as the lithium battery industry and CROs. However, there are still structural opportunities present, particularly in specialized and innovative enterprises [3]. - The recent adjustments to the North Exchange 50 Index, which included high-growth companies in advanced manufacturing and technology sectors, are expected to enhance the index's representation of innovative sectors [3]. - The establishment of various local bond financing subsidy policies is aimed at supporting technology innovation bonds and green bonds, indicating a favorable policy environment for these sectors [2][17]. - The launch of the drug price registration system is anticipated to resolve the pricing reference issues for innovative drugs, potentially attracting more multinational pharmaceutical companies to invest in China [17]. Summary by Sections Market Review - On December 2, the North Exchange A-share trading volume reached 139.4 billion, a decrease of 16.6 billion from the previous trading day. The North Exchange 50 Index closed at 1398.13, down 0.76%, with a PE_TTM of 66.23 times. The specialized and innovative index closed at 2343.26, down 0.84% [7][12]. Stock Performance - Among the 286 companies listed on the North Exchange, 34 saw an increase in stock prices, 5 remained flat, and 247 experienced declines. The top five gainers included Jingchu Electric (330.7%), Kun Gong Technology (7.1%), and Longzhu Technology (6.7%). The top five decliners included Deer Chemical (-6.0%) and Henghe Co. (-5.2%) [14][15]. Important News - Multiple regions have introduced bond financing subsidy policies, with one area offering a subsidy of 400,000 for issuing technology innovation bonds. This reflects a shift towards a multi-faceted support model for local financing initiatives [2]. - The drug price registration system launched on December 2 aims to address the lack of reference pricing for innovative drugs, which could significantly enhance the international competitiveness of Chinese pharmaceuticals [17]. Company Announcements - Ruihua Technology announced the receipt of a patent for a method of preparing high-impact polystyrene, indicating ongoing innovation within the company [18]. - Gobi Jia disclosed plans for a shareholder to reduce holdings by up to 2.8 million shares, representing 1.94% of total equity, due to operational management needs [19].